MEDICINOVA INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| MEDICINOVA, INC. | ||
| A Delaware Corporation | ||
| Date: February 15, 2024 | By: | /s/ Yuichi Iwaki |
|---|---|---|
| Yuichi Iwaki, M.D., Ph.D. | ||
| President & Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Yuichi Iwaki his or her true and lawful attorney-in-fact, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his or her substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Yuichi IwakiYuichi Iwaki, M.D., Ph.D. | Chairman of the Board of Directors, President and Chief Executive Officer (Principal executive officer) | February 15, 2024 |
| /s/ Jason KrugerJason Kruger | Chief Financial Officer(Principal financial and accounting officer) | February 15, 2024 |
| /s/ Carolyn BeaverCarolyn Beaver | Director | February 15, 2024 |
| /s/ Nicole LemerondNicole Lemerond | Director | February 15, 2024 |
| /s/ Kazuko MatsudaKazuko Matsuda | Director | February 15, 2024 |
| /s/ Hideki NagaoHideki Nagao | Director | February 15, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.